![](\"https:\/\/mms.businesswire.com\/media\/20260521298687\/en\/2812441\/22\/2402311PRESS_RELEASE-BizWire.jpg\")
<\/a>![](\"https:\/\/mms.businesswire.com\/media\/20260521298687\/en\/2812441\/21\/2402311PRESS_RELEASE-BizWire.jpg\")
<\/a>![](\"https:\/\/mms.businesswire.com\/media\/20260521298687\/en\/722009\/22\/MTF_FINAL_LOGO.jpg\"){kind=logo}
<\/a>![](\"https:\/\/mms.businesswire.com\/media\/20260521298687\/en\/722009\/21\/MTF_FINAL_LOGO.jpg\"){kind=logo}
<\/a>\nThe agreement combines AmnioBand's<\/b> peer-reviewed Level 1 clinical evidence base with NHMS's specialized provider network and hands-on field support, creating a distribution model purpose-built for the complex realities of outpatient and mobile wound care. Clinicians gain consistent allograft access, expert point-of-care support, and the confidence of broad payer coverage through commercial and Medicare health plans reaching more than 280 million Americans.<\/p>
\n\u201cWound care specialists and podiatrists deserve a solution they can trust; one backed by real clinical evidence, consistent payer access, and an uncompromising standard for quality and safety. New Horizon Medical Solutions\u2019 exclusive focus on this patient population and their depth of provider relationships make them the right partner to expand that access.\u201d<\/i> - Joe Yaccarino, President & Chief Executive Officer, MTF Biologics<\/b><\/p>
\nNHMS was selected for its dedicated wound care model, which integrates clinical field teams, established provider relationships, and practice infrastructure specifically designed for wound care and podiatry settings. The company\u2019s singular focus on this patient population enables a level of clinical support and practice integration that broad-line distributors cannot match.<\/p>
\n\u201cThe wound care clinicians we work with are managing complex patients under real payer and documentation pressure. They need a tissue solution with the clinical evidence to support their treatment decisions and the coverage reliability to make it practice-viable. AmnioBand delivers both. Our exclusive relationship ensures our providers will have consistent allograft access, expert clinical support at the point of care, and a partner they can count on now and long term.\u201d<\/i> - Will Hall, Chief Executive Officer, New Horizon Medical Solutions<\/b><\/p>
\nThe agreement reflects MTF Biologics\u2019 mission to save and heal lives by expanding patient access to evidence-supported tissue solutions and underscores NHMS\u2019s commitment to equipping wound care providers with the clinical tools and practice support they need to deliver better outcomes.<\/p>
\nKEY HIGHLIGHTS<\/b><\/p> \nAbout AmnioBand\u00ae<\/sup><\/b><\/p> \nAmnioBand\u00ae<\/sup> Membrane is a bilayer amnion\/chorion placental allograft processed under aseptic processing standards with rigorous quality testing. With access across more than 280 million Americans through commercial and Medicare health plans, AmnioBand offers wound care specialists broad coverage and practice efficiency across patient populations. Its clinical foundation includes peer-reviewed publications giving clinicians demonstrated outcomes across wound care applications.<\/p> \nFor more information about MTF Biologics and New Horizon Medical Solutions, visit www.mtfbiologics.org<\/a> and www.nhmedical.com<\/a>.<\/p> \nAbout MTF Biologics<\/b><\/p> \nMTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science. In partnership with organ and tissue recovery organizations, MTF Biologics provides exceptional services, resources, and expertise to donors and their families; tissue and organ transplant patients; and clinicians and scientists who advance patient care.<\/p> \nThe International Institute for the Advancement of Medicine (IIAM), a Division of MTF Biologics, honors donors of non-transplantable organs by providing their gifts to the medical research community to combat and cure diseases. Statline, also a Division of MTF Biologics, provides specialized screening, coordination, and communications services to organ transplant centers, organ, tissue, and eye procurement organizations, and the hospitals and patients that they serve. Its sister organization, Deutsches Institut f\u00fcr Zell-und Gewebeersatz \u2013 DIZG (The German Institute for Cell and Tissue Transplantation) expands its reach to patients across the globe.<\/p> \nAbout New Horizon Medical Solutions<\/b><\/p> \nNew Horizon Medical Solutions is a forward-thinking company specializing in advanced wound care technologies, committed to developing and delivering biologically derived human placental allograft products that meet the highest safety and performance standards. NHMS's product portfolio includes amniotic tissues, micro autologous skin grafting, and wound care devices for wound imaging and debridement for chronic wounds, surgical reconstruction, burns, and orthopedic procedures. Through evidence-based design and precision manufacturing, NHMS strives to enhance patient outcomes in clinical practice.<\/p> \nMedia Contacts:<\/b>\n